CLEVELAND, March 11 /PRNewswire/ -- ChanTest, the leading provider of ion channel testing services for drug discovery and development customers, will feature the latest in its expanding line of services in booth 2504 at the Society of Toxicology conference March 17-20, in Seattle, Washington. New FDA Critical Path safety profiling tools include the Cardiac Channel Panel(TM) and Brain Channel Panel(TM), which ChanTest designed to complement the FDA and ICH S7A safety guidance, as well as the Pain/Inflammation and Epilepsy Channel Panels for profiling by therapeutic target. ChanTest has validated the panels against the "gold standard" manual patch clamp to ensure that results from early screens will correlate during the GLP studies that are required for IND submission.
According to Dr. Arthur (Buzz) Brown, founder and CEO of ChanTest, "At ChanTest, we've designed our comprehensive range of ion channel assays, follow-up models, and consultation services to give customers the early answers they need to identify the most-promising drug targets, and eliminate those that could be harmful - before they invest millions on clinical trials. ChanTest is the most experienced ion channel services company in the world. Our scientific team is dedicated to providing the individual attention customers need to move their project successfully through the IND process. We work closely with customers worldwide to design a testing program that meets their drug discovery, safety, regulatory, and budgetary goals. Then, we use the latest screening techniques and proprietary assays to deliver fast, accurate, and reliable results. We specialize in ion channel screening. Customers count on ChanTest because we don't just deliver raw data - our ion channel experts tell customers what the results mean."
ChanTest scientists were the first to prove hERG as the target for
adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine),
Propulsid (cisapride), and Nizoral
Copyright©2008 PR Newswire.
All rights reserved